MARC SCIENTIFIC ADVISORY BOARD
The MARC has assembled a group of distinguished researchers in addictions science, neurobiology, and neuroimmunology to serve as our scientific advisory board (SAB). The group meets periodically with our investigators, reviews progress reports, and helps evaluate our pilot-project applicantions. In addition, SAB members may be asked to advise individual members of the MARC as specific issues arise.
Dr. Bourdette is Chair and Roy & Eulalia Swank Family Research Professor with OHSU's Department of Neurology as well as director of the Multiple Sclerosis Center of Oregon. His research interests include the pathogenesis of multiple sclerosis and development of new treatment approaches for the disease.
Dr. Marshall's work includes research on brain recovery following injury, cellular factors contributing to neurodegeneration, organization of basal ganglia motor systems, and computer-assisted quantitative localization of transmitter receptors in the central nervous system.
Dr. Paulus' work focuses on how decision-making dysfunctions contribute to the transition from casual use of drugs to dependence and how these dysfunctions contribute to relapse in individuals with stimulant dependence.
Dr. Robinson's research interests include neuropsychopharmacology; neurobiology of addiction; long-term effects of psychomotor stimulant drugs and stress on brain and behavior; neural adaptations to brain damage; and brain dopamine systems.
Dr. Yamamoto's primary research interests lie in neuropharmacology, neurodegeneration, and the neurotoxicity of the amphetamines. The overall hypothesis is that the amphetamines, through the enhanced release of dopamine and glutamate, promote excitotoxicity, free-radical mediated oxidative stress, and produce a compromised bioenergetic state that damage dopamine and 5HT neurons.
John Williams, Ph.D.
Vollum Institute for Advanced Biomedical Research
Dr. Williams is an authority on the responses of neuronal systems to abused drugs, measured using electrophysiological methods. He and his colleagues investigate the early events that lead to the development of tolerance to opioids.
Dr. Zahniser researches the interactions of abused drugs with aminergic transporters and the disposition of neurotransmitters.